Navigation Links
Comparing Psoriasis Treatments

A new study shows two common treatments for psoriasis -- methotrexate and cyclosporine -- are equally effective in relieving symptoms of the disease. //

Researchers in Amsterdam studied nearly 90 patients with moderate-to-severe psoriasis. Half of the patients were given methotrexate, and the other half were treated with cyclosporine. Researchers evaluated the side effects and effectiveness of each drug. They also recorded the time patients were in remission and assessed their quality of life. None of the participants had previously been treated with methotrexate or cyclosporine.

Results of the study show the overall response rate for both drugs was more than 90 percent. Seventeen patients in the methotrexate group and 14 patients in the cyclosporine group reached nearly complete remission. Twenty-six patients in the methotrexate group and 30 patients in the cyclosporine group achieved partial remission. However, after 16 weeks of treatment, no significant difference in overall effectiveness was seen between the two groups.

More than 100 patients in the methotrexate group and more than 150 patients in the cyclosporine group reported side effects. More patients in the methotrexate group reported nausea, and patients in the cyclosporine group were more likely to report headaches. There were no significant reported differences in quality of life between the two groups.

Authors of the study say the overall effectiveness of methotrexate is similar to that of cyclosporine. They conclude, "Differences between the treatments in terms of side effects, long-term adverse effects, ease of administration, and costs can be used to guide treatment decisions in individual cases."
'"/>




Page: 1

Related medicine news :

1. Comparing Breast surgery techniques
2. Comparing heart disease treatments
3. New and unique treatment for Psoriasis patients
4. Psoriasis Increases Cancer Risk
5. Help for Psoriasis
6. Managing Patients With Psoriasis
7. Effective Treatment Option For Psoriasis
8. Smoking Aggravates Psoriasis
9. Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder
10. Short-Term Topical Corticosteroid May Offer Relief for Certain Type of Psoriasis
11. Psoriasis raises risk for heart attack
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief ... advancements to physician colleagues, skilled nursing facility medical directors and other clinicians at ... of Wound Care." , "At many of these conferences we get to educate ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: